AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AROVELLA THERAPEUTICS LTD

0.094

-0.005-5.05%

Volume:1.14M

Turnover:110.09K

Market Cap:112.91M

PE:-13.74

High:0.098

Open:0.098

Low:0.094

Close:0.099

52wk High:0.195

52wk Low:0.068

Shares:1.20B

Float Shares:895.86M

Volume Ratio:0.86

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.007

EPS(LYR):-0.007

ROE:-47.98%

ROA:-28.30%

PB:5.62

PE(LYR):-13.74

Loading ...

Overview Company News Filings

Arovella Therapeutics Interim Chair Retires; Shares Up 4%

MT Newswires Live

Arovella Therapeutics - Elizabeth Stoner Will Be Retiring as Interim Chair

THOMSON REUTERS

Arovella Therapeutics Ltd-Board Changes

THOMSON REUTERS

Arovella Therapeutics Ltd-Letter From Managing Director and CEO

THOMSON REUTERS

Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate

MT Newswires Live

BRIEF-Arovella Therapeutics Says IND For Ala-101 Accepted By FDA

Arovella Therapeutics Ltd - Ind for Ala-101 Accepted by U.s.FDA

THOMSON REUTERS

BRIEF-Arovella Therapeutics Appoints Lachie Mallia As CFO

Arovella Therapeutics Ltd-Company Secretary/CFO Appointment/Resignation

THOMSON REUTERS

Arovella Therapeutics (ASX:ALA) jumps 21% this week, taking three-year gains to 288%

Simply Wall St.

BUZZ-Australia's Arovella Therapeutics jumps on US FDA application for human trials

BRIEF-Arovella Therapeutics Files IND Application With US FDA For First-In-Human Phase 1 Trial Of ALA-101

Arovella Therapeutics Ltd - Files Ind Application With U.S. FDA for First-in-Human Phase 1 Trial of Ala-101

THOMSON REUTERS

Arovella Therapeutics Ltd-Appointment of DR Andrew Nash as Non-Executive Director

THOMSON REUTERS

Arovella Therapeutics Launches Phase 1 Trial for ALA-101 iNKT Cell Therapy

MT Newswires Live

Arovella Therapeutics Ltd-Arovella Progresses Ala-101 Program With Appointment of Phas

THOMSON REUTERS

Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%

MT Newswires Live

Arovella Therapeutics to Receive US Patent Allowance for Blood Cancer Cell Therapy Platform; Shares Rise 5%

MT Newswires Live

BRIEF-Arovella Therapeutics Says US Patent Application For Arovella's CAR-INKT Cell Platform To Proceed To Grant

Arovella Therapeutics Ltd - US Patent Application for Arovella's Car-Inkt Cell Platform to Proceed to Grant

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALA.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.094,"timestamp":1770786720000,"preClose":0.099,"halted":0,"volume":1138257,"delay":0,"changeRate":-0.050505050505050546,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1201183672,"eps":-0.006843,"marketStatus":"Not Yet Opened","change":-0.005,"latestTime":"02-11 16:12:00 AEDT","open":0.098,"high":0.098,"low":0.094,"amount":110086,"amplitude":0.040404,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.006843,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770850800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.099,"openAndCloseTimeList":[[1770764400000,1770786000000]],"volumeRatio":0.8611074883011814,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-28.30%","roe":"-47.98%","lyrEps":-0.006843,"volumeRatio":0.8611074883011814,"shares":1201183672,"dividePrice":0,"high":0.098,"amplitude":0.040404,"preClose":0.099,"low":0.094,"week52Low":0.068,"pbRate":"5.62","psRate":"32.82","week52High":0.195,"institutionHeld":0,"latestPrice":0.094,"eps":-0.006843,"divideRate":0,"volume":1138257,"delay":0,"ttmEps":-0.006843,"open":0.098,"prevYearClose":0.093,"prevWeekClose":0.09,"prevMonthClose":0.086,"prevQuarterClose":0.093,"fiveDayClose":0.095,"twentyDayClose":0.088,"sixtyDayClose":0.092},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610916505","title":"Arovella Therapeutics Interim Chair Retires; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610916505","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610916505?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:58","pubTimestamp":1770595091,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  said that interim Chair Elizabeth Stoner has retired, effective Monday, according to a same-day Australian bourse filing.The company will provide updates regarding the appointment of a new chair following the completion of a skills review, the filing added.The company's shares rose 4% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK4539","BK7096","BK4139","ALA.AU"],"gpt_icon":0},{"id":"2610950311","title":"Arovella Therapeutics - Elizabeth Stoner Will Be Retiring as Interim Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2610950311","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610950311?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:00","pubTimestamp":1770591641,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUEB9CV11:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2610161503","title":"Arovella Therapeutics Ltd-Board Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2610161503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610161503?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:00","pubTimestamp":1770591641,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUEB9CV11:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2609165883","title":"Arovella Therapeutics Ltd-Letter From Managing Director and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2609165883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609165883?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:42","pubTimestamp":1770241363,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUE35N0XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2607977190","title":"Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2607977190","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607977190?lang=en_us&edition=fundamental","pubTime":"2026-01-29 12:20","pubTimestamp":1769660439,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical tria","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4539","BK4007","ALA.AU","BK7096"],"gpt_icon":0},{"id":"2607209517","title":"BRIEF-Arovella Therapeutics Says IND For Ala-101 Accepted By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2607209517","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607209517?lang=en_us&edition=fundamental","pubTime":"2026-01-29 09:25","pubTimestamp":1769649914,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Says IND For Ala-101 Accepted By FDAJan 29 (Reuters) - Arovella Therapeutics ALA.AX:IND FOR ALA-101 ACCEPTED BY U.S.FDAFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YT16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2607093725","title":"Arovella Therapeutics Ltd - Ind for Ala-101 Accepted by U.s.FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2607093725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607093725?lang=en_us&edition=fundamental","pubTime":"2026-01-29 06:11","pubTimestamp":1769638314,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2605320664","title":"BRIEF-Arovella Therapeutics Appoints Lachie Mallia As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605320664","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605320664?lang=en_us&edition=fundamental","pubTime":"2026-01-22 08:50","pubTimestamp":1769043049,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Appoints Lachie Mallia As CFOJan 22 (Reuters) - Arovella Therapeutics Ltd ALA.AX:COMPANY SECRETARY/CFO APPOINTMENT/RESIGNATIONAPPOINTS LACHIE MALLIA AS CFOFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUE7GGP57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2605743375","title":"Arovella Therapeutics Ltd-Company Secretary/CFO Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2605743375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605743375?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:32","pubTimestamp":1769031124,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUE7GGP57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2600707839","title":"Arovella Therapeutics (ASX:ALA) jumps 21% this week, taking three-year gains to 288%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600707839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600707839?lang=en_us&edition=fundamental","pubTime":"2026-01-01 04:01","pubTimestamp":1767211279,"startTime":"0","endTime":"0","summary":"The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ala/arovella-therapeutics-shares/news/arovella-therapeutics-asxala-jumps-21-this-week-taking-three","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ala/arovella-therapeutics-shares/news/arovella-therapeutics-asxala-jumps-21-this-week-taking-three","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2595750478","title":"BUZZ-Australia's Arovella Therapeutics jumps on US FDA application for human trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2595750478","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595750478?lang=en_us&edition=fundamental","pubTime":"2025-12-30 10:51","pubTimestamp":1767063090,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Arovella Therapeutics jumps on US FDA application for human trials** Shares of Arovella Therapeutics ALA.AX jump as much as 10.6% to A$0.084, its biggest intraday pct jump in three months** Stock hits highest level since Dec 1 after submitting Investigational New Drug  application to U.S. FDA for cell therapy candidate ALA-101** Co says IND application to progress ALA-101 towards first-in-human Phase 1 clinical trial, pending FDA clearance** ALA-101 targets specific cancer cells to treat lymphoma and leukemia** ALA down almost 52% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nL6N3Y0026:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2595547297","title":"BRIEF-Arovella Therapeutics Files IND Application With US FDA For First-In-Human Phase 1 Trial Of ALA-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2595547297","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595547297?lang=en_us&edition=fundamental","pubTime":"2025-12-30 09:20","pubTimestamp":1767057639,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Files IND Application With US FDA For First-In-Human Phase 1 Trial Of ALA-101Dec 30  - Arovella Therapeutics Ltd ALA.AX:FILES IND APPLICATION WITH U.S. FDA FOR FIRST-IN-HUMAN PHASE 1 TRIAL OF ALA-101Further company coverage: ALA.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3XY08B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2595754465","title":"Arovella Therapeutics Ltd -  Files Ind Application With U.S. FDA for First-in-Human Phase 1 Trial of Ala-101","url":"https://stock-news.laohu8.com/highlight/detail?id=2595754465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595754465?lang=en_us&edition=fundamental","pubTime":"2025-12-30 09:18","pubTimestamp":1767057535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3XY08B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2582085390","title":"Arovella Therapeutics Ltd-Appointment of DR Andrew Nash as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2582085390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582085390?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:51","pubTimestamp":1762897904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUE3LMQDF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2579940059","title":"Arovella Therapeutics Launches Phase 1 Trial for ALA-101 iNKT Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2579940059","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579940059?lang=en_us&edition=fundamental","pubTime":"2025-10-29 14:01","pubTimestamp":1761717688,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  has launched start-up activities for its phase 1 ALA-101 trial, partnering with SAPRO as its contract research organization to progress its invariant Natural Killer T  cell therapy platform, according to a Wednesday filing with the Australian bourse.The dose escalation phase of the trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy to determine the maximum tolerated dose, which the expansion phase will further evaluate, the filing said.The first-in-human, open-label trial will use dose escalation and expansion to evaluate ALA-101 in CD19-positive non-Hodgkin's lymphoma and leukemia, with initial sites in Australia and New Zealand, per the filing.The trial will use a Bayesian design to optimize dosing and safety and is awaiting ethics and institutional approvals, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK4539","XAO.AU","LENZ","ALA.AU","BK4139","XJO.AU","BK4007","BK7096"],"gpt_icon":0},{"id":"2579108149","title":"Arovella Therapeutics Ltd-Arovella Progresses Ala-101 Program With Appointment of Phas","url":"https://stock-news.laohu8.com/highlight/detail?id=2579108149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579108149?lang=en_us&edition=fundamental","pubTime":"2025-10-29 09:07","pubTimestamp":1761700039,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUE1BGZWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2572672375","title":"Arovella Therapeutics Study Demonstrates CLDN18.2 CAR-T Cells Eliminate Pancreatic Cancer Cells, Shares Jump Over 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572672375","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572672375?lang=en_us&edition=fundamental","pubTime":"2025-10-02 10:21","pubTimestamp":1759371693,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  confirmed the functionality of its claudin 18.2 -targeting chimeric antigen receptor by demonstrating that CLDN18.2 chimeric antigen receptor-T  cells eliminate pancreatic cancer cells that express CLDN18.2 in a proof-of-concept in vitro study, according to a Thursday Australian bourse filing.Arovella's chimeric antigen receptor design is based on the patent-protected CLDN18.2 antigen-binding sequences of the SPX-101 monoclonal antibody, for which the firm has an exclusive license for use in cell therapies.The study was performed at the University of North Carolina. The human pancreatic adenocarcinoma cell line, PaTu8892S, which expresses CLDN18.2, was selected as a model cell line for this study. CLDN18.2 CAR-T cells, generated from three independent donors, were cultured in vitro with twice the number of PaTu8892S cells for three days. After this, the degree of cytotoxicity was measured.The firm's shares jumped over 13% in recent trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4022","LENZ","CAR","BK4539","ALA.AU","BK4230","BK4007","BK4139"],"gpt_icon":0},{"id":"2562706090","title":"Arovella Therapeutics to Receive US Patent Allowance for Blood Cancer Cell Therapy Platform; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562706090","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562706090?lang=en_us&edition=fundamental","pubTime":"2025-08-28 11:53","pubTimestamp":1756353230,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  has received a Notice of Allowance from the US Patent and Trademark Office for a patent covering its invariant Natural Killer T  cell therapy platform to treat blood cancers and solid tumours, according to a Thursday filing with the Australian bourse.The patent covers the manufacturing of Chimeric Antigen Receptor -iNKT cells and once granted will offer protection in the US until at least Feb. 28, 2039, the filing said.Shares of the company rose 5% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAR","BK4230","LENZ","BK4139","BK7002","BK4007","BK7503","BK4022","BK4539","BK7096","CAR.AU","ALA.AU"],"gpt_icon":0},{"id":"2562038937","title":"BRIEF-Arovella Therapeutics Says US Patent Application For Arovella's CAR-INKT Cell Platform To Proceed To Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2562038937","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562038937?lang=en_us&edition=fundamental","pubTime":"2025-08-28 10:17","pubTimestamp":1756347422,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Says US Patent Application For Arovella's CAR-INKT Cell Platform To Proceed To GrantAug 28  - Arovella Therapeutics Ltd ALA.AX:US PATENT APPLICATION FOR AROVELLA'S CAR-INKT CELL PLATFORM TO PROCEED TO GRANTFurther company coverage: ALA.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nFWN3UJ10N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2562775083","title":"Arovella Therapeutics Ltd - US Patent Application for Arovella's Car-Inkt Cell Platform to Proceed to Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2562775083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562775083?lang=en_us&edition=fundamental","pubTime":"2025-08-28 06:28","pubTimestamp":1756333718,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nFWN3UJ10N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}]}}